Ziyuglycoside I
Ziyuglycoside I has anti-wrinkle activity, could be used as an active ingredient for cosmetics.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Appl. Sci.2021, 11(19),9343.
Biochem Pharmacol.2020, 178:114083
Life (Basel).2022, 12(12):2107.
Free Radic Biol Med.2017, 112:191-199
Molecules.2020, 25(20):4851.
Molecules.2021, 26(9):2765.
Reprod Sci.2022,10.1007/s43032-022-01117-4.
Turk J Med Sci.2023 53: 1312-1320.
Molecules.2021, 26(13):4081.
J Nat Med.2020, 74(1):65-75
Related and Featured Products
Biosci Biotechnol Biochem. 2008 Feb;72(2):303-11.
Anti-wrinkle activity of ziyuglycoside I isolated from a Sanguisorba officinalis root extract and its application as a cosmeceutical ingredient.[Pubmed:
18256460]
In order to investigate the potential of a Sanguisorba officinalis root extract as an active ingredient for wrinkle-care cosmetics, we measured its free radical scavenging activity, elastase inhibitory activity, expression of MMP-1 (matrix metalloprotease-1) in vitro, and type I collagen synthesis in normal human fibroblast cells.
METHODS AND RESULTS:
To isolate the main components from the S. officinalis root extract, we purified the extract by solvent fractionation, column chromatography, and recrystallization. The active component was identified as Ziyuglycoside I by a spectroscopic analysis. Ziyuglycoside I increased the expression of type I collagen in a dose-dependent manner (by up to 71.3% at 50 muM). A clinical study of a formulation containing Ziyuglycoside I, which involved visual evaluation and image analysis, showed a significantly different effect (p<0.05) of the test formulation from that of the placebo.
CONCLUSIONS:
This result suggests that Ziyuglycoside I isolated from S. officinalis root extract could be used as an active ingredient for cosmetics.
Int J Mol Sci . 2016 Nov 22;17(11):1903.
Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis[Pubmed:
27879682]
Abstract
Background: Due to the aggressive clinical behavior, poor outcome, and lack of effective specific targeted therapies, triple-negative breast cancer (TNBC) has currently been recognized as one of the most malignant types of tumors. In the present study, we investigated the cytotoxic effect of Ziyuglycoside I, one of the major components extracted from Chinese anti-tumor herbal Radix Sanguisorbae, on the TNBC cell line MDA-MB-231.
Methods: The underlying molecular mechanism of the cytotoxic effect Ziyuglycoside I on MDA-MB-231 cells was investigated with cell viability assay, flow cytometric analysis and Western blot.
Results: Compared to normal mammary gland Hs 578Bst cells, treatment of Ziyuglycoside I resulted in a significant growth inhibitory effect on MDA-MB-231 cells. Ziyuglycoside I induced the G2/M phase arrest and apoptosis of MDA-MB-231 cells in a dose-dependent manner. These effects were found to be partially mediated through the up-regulation of p53 and p21WAF1, elevated Bax/Bcl-2 ratio, and the activation of both intrinsic (mitochondrial-initiated) and extrinsic (Fas/FasL-initiated) apoptotic pathways. Furthermore, the p53 specific siRNA attenuated these effects.
Conclusion: Our study suggested that Ziyuglycoside I-triggered MDA-MB-231 cell cycle arrest and apoptosis were probably mediated by p53. This suggests that Ziyuglycoside I might be a potential drug candidate for treating TNBC.
Keywords: G2/M phase arrest; MDA-MB-231 cell line; intrinsic and extrinsic apoptosis; Ziyuglycoside I.
J Sep Sci. 2015 Apr 17.
Development and validation of a quantification method for ziyuglycoside I and II in rat plasma: Application to their pharmacokinetic studies.[Pubmed:
25885584]
This study provided a novel and generally applicable method to determine Ziyuglycoside I and Ziyuglycoside II in rat plasma based on liquid chromatography with tandem mass spectrometry.
METHODS AND RESULTS:
A single step of liquid-liquid extraction with n-butanol was utilized, and ginsenoside Rg3 was chosen as internal standard. Final extracts were analyzed based on liquid chromatography with tandem mass spectrometry. Chromatographic separation was achieved using a Thermo Golden C18 column, and the applied gradient elution program allowed for the simultaneous determination of two ziyuglycosides in a one-step chromatographic separation with a total run time of 10 min. The fully validated methodology for both analytes demonstrated high sensitivity (the lower limit of quantitation was 2.0 ng/mL), good accuracy (% RE ≤ ± 15) and precision (% RSD ≤ 15). The average recoveries of both ziyuglycosides and internal standard were all above 75% and no obvious matrix effect was found. This method was then successfully applied to the preclinical pharmacokinetic studies of Ziyuglycoside I and Ziyuglycoside II.
CONCLUSIONS:
The presently developed methodology would be useful for the preclinical and clinical pharmacokinetic studies for Ziyuglycoside I and Ziyuglycoside II.
